Immunomedics Warns Biosimilar Chasers Over Trodelvy
Sacituzumab Biologic Brand Was Approved By FDA In April
Executive Summary
Biosimilar sponsors know well the challenges to approval. Immunomedics, which in April obtained FDA approval for the Trodelvy oncology biologic, has suggested the barriers for competitors to the brand may be insurmountable for some time.
You may also be interested in...
Gilead’s Immunomedics Buy: Five Things To Worry About
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.
Immunomedics' Trodelvy Will Be First ADC For Triple-Negative Breast Cancer
Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.
FDA Guides On Adding Biosimilar Indications
Sponsors may submit supplemental applications for additional indications in advance so that approval will coincide with expiration of a reference product’s exclusivity or patent protection, new draft guidance states; agency targets six-month review of such supplements, rather than the 10 months provided under BsUFA II.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: